Document is current

Article History

Accepted: 11 April 2024

First Online: 9 May 2024

Declarations

:

: No funding was received for the preparation of this article.

: Vera Bril has consulted for Grifols, CSL, UCB, Argenx, Takeda, Alnylam Octapharma, Pfizer, Powell Mansfield Inc., Akcea, Ionis, Immunovant, Sanofi, Momenta (Johnson & Johnson), Roche, Janssen, AZ-Alexion, NovoNordisk, and Japan Tobacco and has received research support from AZ-Alexion, Grifols, CSL, UCB, Argenx, Takeda, Octapharma, Akcea, Momenta (Johnson & Johnson), Immunovant, and Ionis. Nouf Alfaidi, Salama Karmastaji, and Alexandria Matic have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: NA: design of work, acquisition, analysis and interpretation of data, drafting the work, and revisions. SK: design of work, acquisition, analysis and interpretation of data, drafting the work, and revisions. AM: design of work, acquisition, analysis and interpretation of data, drafting the work, and revisions. VB: design of work, drafting the work, analysis of data, revising it critically, and final approval of version to be published. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.